SEC accuses Merck exec of insider trading

In a civil suit filed in Philadelphia, the SEC accused James Self, 45, an executive director at Merck, of feeding his business school buddy and former hedge fund manager Stephen Goldfield, 46, the details of a 2007 Merck deal to buy drug firm MedImmune. Report